Nanotechnology
A new report from Baqiyatallah University of Medical Sciences highlights the potential of nanoparticles in combating infection and gastric cancer. The research, presented in a review article, emphasizes the need for novel drug delivery systems that can effectively target and treat this persistent health problem. According to the study, conventional
Nanotechnology
Recent advancements in nanotechnology have significantly improved therapeutic outcomes in mitigating chronic inflammation and cancer, offering a promising approach to cancer prevention and therapy. Researchers from the School of Bioscience and Technology have made significant progress in developing nanocarriers that can encapsulate nonsteroidal anti-inflammatory drugs (NSAIDs), improving pharmacokinetics and pharmacodynamics,
Nanotechnology
Researchers from Northwest A&F University have made a significant discovery in the field of melanoma immunotherapy, developing a novel nanomotor system that synergistically enhances the treatment efficacy against cancer. The study, published in the Journal of Colloid and Interface Science, reveals that the nanomotor system can effectively penetrate
Nanotechnology
A new research study has made significant strides in the treatment of breast cancer, demonstrating the potential of nanostraw-assisted injection to enhance photothermal therapy (PTT). The study, led by researchers from Sao Paulo State University (UNESP), has shown that the use of nanostraw-assisted injection can improve the efficacy of PTT
Biological products industry
Aspire Biopharma Holdings, a developer of a patent-pending drug delivery technology, is set to present at the Sidoti Virtual Investor Conference on May 21. The company's CEO, Kraig Higginson, will lead the presentation, which will be accessible via the virtual conference platform. Additionally, Aspire Biopharma will host virtual
Pharmaceutical industry
Biovail Corporation International, a leading pharmaceutical company, has announced a 2-for-1 stock split and an employee stock purchase plan. The special shareholder meeting to approve the stock split will be held on January 2, 1996, and shareholders will be notified and receive new stock certificates reflecting the split. The company
Pharmaceutical industry
R.P. Scherer Corporation and Sandoz Pharma Ltd. have mutually agreed to renew their collaborative agreement for the manufacture of soft gelatin capsules for SANDIMMUN(R) (cyclosporin) and its successor, SANDIMMUN-NEORAL(R), until the year 2002. This partnership has been instrumental in revolutionizing organ transplantation with SANDIMMUN(R), a drug
Drugs
Therapeutic Discovery Corporation (TDC), a biotechnology company based in Palo Alto, California, has announced its second-quarter financial results for 1995. The company reported a net loss of $11.1 million, or $1.44 per common share, for the quarter ended June 30, 1995. This compares to a net loss of
Drugs
Ethical Holdings plc, a specialist drug delivery group, has reported a significant increase in revenues for the third quarter of 1995, with a loss of £1.26 million. The Group's revenues increased by 32 percent to £2.71 million from £2.06 million in the same period in
Medical equipment industry
CYTOGEN Corporation has reported a decrease in operating expenses by 16% in 1994 and reaffirmed its commitment to reducing and controlling spending in 1995. The company's financial results for 1994, highlighted by a decrease in total revenues to $2.5 million compared to $10.4 million in 1993,
Medical equipment industry
CIMA Labs Inc., a drug delivery company founded in 1987, has completed the manufacturing facility for its OraSolv(R) technology-based products. The 75,000 square foot facility, located in Eden Prairie, Minnesota, has an initial production capacity of 400 million tablets per year and can be expanded to six production
Pharmaceutical industry
CIMA Labs Inc. announced financial results for 1994, with revenue of $2.6 million, expenses of $9.3 million, and a net loss of $6.2 million. Despite the net loss, the company achieved significant milestones, including agreements with multinational pharmaceutical companies such as Pfizer Inc., Sterling Winthrop, Inc., and
